MyBiotics Pharma is a microbiome company focused on bettering peoples lives and health by greatly improving on existing probiotic solutions. MyBiotics has developed a novel technological platform for the development of microbiome-related drugs and supplements. The companys platform uses innovative formulation, delivery, and culturing methods designed to provide better viability and resistance, and potentially improved colonization and clinical results. Based on this proprietary innovation, MyBiotics has developed three main technologies: MyCrobe, SuperDonor, and Super Donor Select, which are all supported by MyLiveIn, a computational and AI technology platform. After targeting specific medical indications, MyBiotics has now reached the clinical stage with three products. Based on the companys SuperDonor technology, its MBX-SD-201 and MBX-SD-202 products offer safe and reproducible microbiome restoration and may become an alternative for complete microbiome recovery and design using fecal microbiota transplantation. MyBiotics has initiated significant collaborations and development agreements with a variety of pharmaceutical companies and clinical partners in the areas of C. diff, oncology, dermatology, and womens health.